Can-Fite BioPharma Ltd (CANF) has released an update.
Can-Fite BioPharma Ltd. has announced that its drug candidate Namodenoson, with potential to treat advanced liver cancer and MASH, is currently under Phase III trial approved by the FDA and EMA, and a Phase IIb study, respectively. The drug has shown promise in pre-clinical and clinical activity by offering dual benefits through anti-cancer activity and liver protection. Namodenoson’s safety and efficacy have been supported by clinical data and its unique mechanism of action, which targets both inflammatory and positive cytokines.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
